Is Your Beauty Manufacturer Ready for MoCRA Facility Registration Renewal?

Quick Answer: MoCRA facility registration renewal requires every cosmetic manufacturing facility to re-register with the FDA every two years. Over 14,000 facilities are currently registered, and the first renewal cycle is active in 2026. A lapsed registration renders products misbranded or adulterated under federal law and exposes brands to enforcement and supply chain disruption.

MoCRA facility registration renewal is the biennial re-registration requirement for every establishment that manufactures or processes cosmetic products distributed in the United States. Under Section 607(a)(2) of the Federal Food, Drug, and Cosmetic Act, every registered facility must renew its registration every two years.

The Modernization of Cosmetics Regulation Act of 2022 ended the cosmetics industry's decades-long voluntary registration system. The FDA announced on February 11, 2026, that over 14,000 cosmetic product facilities are currently registered with the agency. Renewal dates are calculated individually based on each facility's initial registration date. Per FDA guidance, renewals can be submitted earlier than the two-year deadline.

The FDA updated its Cosmetics Direct portal on February 11, 2026, to support the first wave of biennial registration renewals. According to the FDA, the portal now displays two new fields: "Registration Status" and "Renewal Date." The agency also implemented automated email reminders sent to all contacts on file.

Cosmetics Direct offers two electronic renewal pathways. The FDA explains that facilities with no changes can use the Abbreviated Renewal option under Section 607(a)(5) of the FD&C Act. Facilities that have updated their name, address, contact details, brand names, or product categories must complete the standard Biennial Renewal. Wiley's regulatory analysis clarifies that MoCRA requires facilities to notify the FDA within 60 days of any changes.

Failure to renew a cosmetic product facility registration is a prohibited act under Section 301(hhh) of the FD&C Act. Respect Manufacturing's compliance guide states that lapsed registration causes products manufactured at the facility to become misbranded or adulterated under federal law. For brands using contract manufacturers, this means every product made there is legally compromised.

CosmeReg's regulatory briefing notes that consequences include FDA enforcement action, warning letters, border holds for imported products, and mandatory recall requirements. Brands cannot sell adulterated cosmetics in the United States, so a manufacturer's registration lapse effectively halts revenue for every SKU produced at that facility.

MoCRA grants the FDA authority to suspend a facility's registration under severe conditions. Per the FDA, the agency may suspend registration if it determines that a product from the facility has a reasonable probability of causing serious adverse health consequences or death, and that the failure is pervasive enough to affect other products manufactured there. When suspension occurs, it becomes a prohibited act to distribute any cosmetic products from that facility in the United States.

MoCRA also requires the FDA to establish binding Good Manufacturing Practice regulations, but the rulemaking has been delayed. Ecomundo's regulatory update reports that the GMP rule was classified as a "long-term action" after the FDA missed its December 2024 statutory deadline. No draft rule is expected in the immediate future. Crowell's analysis confirms the delay but emphasizes that the FDA already expects manufacturers to demonstrate structured manufacturing controls and product safety practices.

For beauty industry operators, the 2026 renewal cycle marks the transition from MoCRA implementation to ongoing regulatory maintenance. Brands that treat facility registration verification as a standard procurement checkpoint will build more resilient supply chains. Contract manufacturer due diligence now includes confirming active FDA registration, accurate renewal timelines, and documented manufacturing controls that anticipate future GMP requirements.

For operators evaluating how automated compliance infrastructure can reduce regulatory risk, solutions like on-demand manufacturing reduce beauty's waste demonstrate how precision manufacturing connects to broader operational outcomes. The question is no longer whether a brand can afford to monitor its manufacturers' MoCRA status. The question is whether it can afford the revenue loss if a supplier's registration lapses.